Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers improve severe asthma care through new, antibody-based treatment


A team of researchers at McMaster University and St. Joseph's Healthcare Hamilton have successfully evaluated a new, antibody-based drug for certain patients with severe asthma.

The drug – named mepolizumab – can replace traditional, steroid-based treatments for a specific subset of patients, resulting in improved outcomes and reduced side effects.

The study and manuscript, published in the New England Journal of Medicine was led in Canada by Dr. Parameswaran Nair, staff respirologist, Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton and professor of respirology at the Michael G. DeGroote School of Medicine at McMaster University. Dr. Nair and his colleagues recruited the largest number of participants for this global study.

"This new drug is the only therapy that has been proven to be effective in well-established clinical trials to help reduce doses of steroid-based treatments such as prednisone for those with severe asthma," said Dr. Nair, adding that the paper reconfirms the team's observation published in the New England Journal of Medicine in 2009.

Patients with severe asthma often require high doses of steroid-based treatments that can significantly impair their quality of life. These high doses can cause debilitating side effects including mood swings, diabetes, bone loss, skin bruising, cataracts and hypertension.

Previous research at the Hamilton institutions has identified specific types of patient with severe asthma have an overabundance of a particular type of white blood cell (eosinophils) present in their sputum. These patients often suffer from the most severe asthma symptoms and can only be treated through steroid-based medications such as prednisone.

"This is an exciting example of personalized medicine for asthma," said Nair. "This discovery now tells us by using a simple blood or sputum eosinophil count, we can identify which asthma patients can benefit from this new treatment. 

Veronica McGuire | Eurek Alert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>